Drugs / Tazocin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00445094 | Nov 2006 → Jan 2007 | pneumonia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT07096310 Comparator | Jan 2024 → Jan 2026 overdue | infectious disease with sepsis | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02894684 Background | Jan 2017 → Feb 2019 | Pseudomonas infection, cystic fibrosis | Liverpool Heart and Chest Hospital NHS Foundation Trust | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tazocin | “14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin” NCT02894684 ↗ |
| Known as | pipercillin/tazobactam | “Tazocin (pipercillin/tazobactam)” NCT07096310 ↗ |
| Route | Intravenous | “Tazocin group will receive non Carbapenems (Tazocin) 4.5 gm IV slow infusion over 20 minutes every 8 hours per day” NCT07096310 ↗ |